Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy of two agents—bleomycin and sodium tetradecyl sulfate (marketed as Fibrovein)—used primarily for sclerotherapy in the treatment of vascular malformations and varicose veins. Bleomycin is a cytotoxic glycopeptide antibiotic with antineoplastic activity, acting mainly by inducing DNA strand breaks through free radical formation. Sodium tetradecyl sulfate is an anionic surfactant that acts as a sclerosant, causing endothelial damage and subsequent fibrosis when injected into veins or vascular lesions. The combination may be used intralesionally to enhance sclerosing efficacy in certain vascular anomalies[3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bleomycin + sodium tetradecyl sulfate.